Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
Stebbing, J., Phelan, A., Griffin, I., Tucker, C., Oechsle, O., Smith, D.(2020) Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Richardson, P., Griffin, I., Tucker, C., Smith, D., Oechsle, O., Phelan, A., Rawling, M., Savory, E.How British covid breakthrough drug was built in record time - revealed (Daily Express press release, 13 November 2021).The background image is a detail from a Creative Commons licensed illustration of SARS-CoV-2 virus. In these unprecedented times, baricitinib received regulatory approval in record time (~10 months).
It generally takes up to 12 years for a drug to receive regulatory approval for use in patients, even if the drug has already been approved for use in other conditions after having undergone safety studies. In April 2021, Japan announced it had approved baricitinib to treat COVID-19. In November 2020, the FDA granted emergency use authorisation for baricitinib in combination with remdesivir to treat COVID-19 in hospitalized patients requiring supplemental oxygen or invasive mechanical ventilation.
#NIGHTMARE ON TRAP STREET MGD TRIAL#
In June 2020, the pharmaceutical company Eli Lilly initiated a large-scale randomised COV-BARRIER phase 3 trial involving 1,525 hospitalized COVID-19 patients demonstrating baricitinib reduced mortality by 38% when combined with standard of care (E.g., corticosteroids and remdesivir). To date, the article has been cited over 1,000 times. In February 2020, they published their first paper in The Lancet proposing baricitinib as a COVID-19 treatment. During the search process, the team discovered baricitinib's previously unknown anti-viral properties, in addition to its anti-inflammatory properties. Baricitinib ( CHEBI:95341), an oral Janus kinase ( JAK) inhibitor approved to treat rheumatoid arthritis and marketed under the brand name Olumiant™ was identified as the most promising treatment from a list of thousands of potential drugs. īy using an artificial intelligence platform, they searched for already approved drugs that could inhibit viral entry into cells and reduce the cytokine storm - a severe and deadly immune response to the virus. In January 2020, shortly after the first news of SARS-CoV-2 virus emerged from Wuhan, China and two months before the World Health Organization ( WHO) declared it a global pandemic - Professor Justin Stebbing (a leading cancer expert) and his team, at Imperial College London, began working on a new therapy for COVID-19.
0 kommentar(er)
